Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 6073-6078, November 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Radomski, M. W.
Right arrow Articles by Moncada, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radomski, M. W.
Right arrow Articles by Moncada, S.

Human Colorectal Adenocarcinoma Cells: Differential Nitric Oxide Synthesis Determines Their Ability to Aggregate Platelets

Marek W. Radomski, David C. Jenkins, Lesley Holmes and Salvador Moncada

The Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, United Kingdom

The existence and role of an L-arginine:nitric oxide (NO) pathway in two human colorectal adenocarcinoma cell lines, SW-480 and SW-620, were investigated. Both cell lines, which derive from the same patient, SW-480 from the primary tumor and SW-620 from its metastatic lesion, were shown to have a cytosolic, Ca2+-independent, NADPH-dependent NO synthase, the activity of which was lower in the cytosol of SW-620. These cells were more potent inducers of platelet aggregation. In contrast, SW-480, which had more NO synthase activity, were less potent inducers of platelet aggregation. Pretreatment of both cell lines with NG-monomethyl-L-arginine, an inhibitor of NO synthase, potentiated their proaggregating effect and made them equally active.

Exogenous L-arginine, NO, and related nitrovasodilators all inhibited platelet aggregation induced by SW-620. The antiaggregating activity of NO was further potentiated by prostacyclin and by M&B22948, a selective inhibitor of cyclic GMP phosphodiesterase. We propose that the generation of NO by tumor cells inversely correlates with their metastatic potential. Furthermore, we show that the lower activity of NO synthase in metastatic cells is due to the presence in these cells of a low molecular weight inhibitor of the NO synthase. In addition, agents which modulate platelet function by a cyclic GMP-dependent mechanism may be useful in the prevention of tumor metastasis.

Received 6/21/91. Accepted 9/11/91.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. Medina, P. Jurasz, M. J. Santos-Martinez, S. S. Jeong, T. Mitsky, R. Chen, and M. W. Radomski
Platelet Aggregation-Induced by Caco-2 Cells: Regulation by Matrix Metalloproteinase-2 and Adenosine Diphosphate
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 739 - 745.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Jurasz, D. Alonso, S. Castro-Blanco, F. Murad, and M. W. Radomski
Generation and role of angiostatin in human platelets
Blood, November 1, 2003; 102(9): 3217 - 3223.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Crowell, V. E. Steele, C. C. Sigman, and J. R. Fay
Is Inducible Nitric Oxide Synthase a Target for Chemoprevention?
Mol. Cancer Ther., August 1, 2003; 2(8): 815 - 823.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Blesson, J. Thiery, C. Gaudin, R. Stancou, J.-P. Kolb, J.-L. Moreau, J. Theze, F. Mami-Chouaib, and S. Chouaib
Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO
Int. Immunol., October 1, 2002; 14(10): 1169 - 1178.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Jurasz, G. Sawicki, M. Duszyk, J. Sawicka, C. Miranda, I. Mayers, and M. W. Radomski
Matrix Metalloproteinase 2 in Tumor Cell-induced Platelet Aggregation: Regulation by Nitric Oxide
Cancer Res., January 1, 2001; 61(1): 376 - 382.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
X. P. Hao, T. G. Pretlow, J. S. Rao, and T. P. Pretlow
Inducible Nitric Oxide Synthase (iNOS) Is Expressed Similarly in Multiple Aberrant Crypt Foci and Colorectal Tumors from the Same Patients
Cancer Res., January 1, 2001; 61(2): 419 - 422.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
R. Singh, S. Pervin, A. Karimi, S. Cederbaum, and G. Chaudhuri
Arginase Activity in Human Breast Cancer Cell Lines: N{{omega}}-Hydroxy-L-arginine Selectively Inhibits Cell Proliferation and Induces Apoptosis in MDA-MB-468 Cells
Cancer Res., June 1, 2000; 60(12): 3305 - 3312.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
Q. Shi, Q. Xiong, B. Wang, X. Le, N. A. Khan, and K. Xie
Influence of Nitric Oxide Synthase II Gene Disruption on Tumor Growth and Metastasis
Cancer Res., May 1, 2000; 60(10): 2579 - 2583.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
Q. Shi, S. Huang, W. Jiang, L. S. Kutach, H. N. Ananthaswamy, and K. Xie
Direct Correlation between Nitric Oxide Synthase II Inducibility and Metastatic Ability of UV-2237 Murine Fibrosarcoma Cells Carrying Mutant p53
Cancer Res., May 1, 1999; 59(9): 2072 - 2075.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.